Login/Sign Up
₹376.2*
MRP ₹418
10% off
₹355.3*
MRP ₹418
15% CB
₹62.7 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Online payment accepted
Provide Delivery Location
Whats That
Country of origin
Alcohol
Unsafe
Alcohol intake might increase the risk of stomach or intestine bleeding. Alcohol consumption is not recommended.
Pregnancy
Unsafe
Metodox 50 mg Injection 1's is not recommended for use in pregnancy as it may harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before receiving Metodox 50 mg Injection 1's. Use reliable methods of birth control while on treatment with Metodox 50 mg Injection 1's.
Breast Feeding
Unsafe
It is not recommended for use in breastfeeding as it may pass into breast milk and harm your infant. Hence, if you are breastfeeding, inform your doctor before receiving Metodox 50 mg Injection 1's. Your doctor may suggest you stop feeding while on treatment with this medicine.
Driving
Not applicable
Metodox 50 mg Injection 1's does not affect your ability to drive.
Liver
Caution
Metodox 50 mg Injection 1's should be used with caution in patients with liver impairment. However, this medicine is contraindicated in patients with severe liver disease. If you have a pre-existing or a history of liver disease, inform your doctor. Your doctor may adjust the dose or prescribe a suitable alternative based on your condition.
Kidney
Caution
If you have a pre-existing or a history of kidney disease, inform your doctor. Your doctor may adjust the dose or prescribe a suitable alternative, if necessary, based on your condition.
Children
Consult your doctor
Metodox 50 mg Injection 1's is used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children). Your doctor may recommend a suitable dosage based on your child's condition.
Product Substitutes
About Metodox 50 mg Injection 1's
Metodox 50 mg Injection 1's is an anti-cancer medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Metodox 50 mg Injection 1's is primarily used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast). It is also used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children).
Metodox 50 mg Injection 1's contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis.
Metodox 50 mg Injection 1's may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, red discoloration of urine, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Metodox 50 mg Injection 1's. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.
Metodox 50 mg Injection 1's should be avoided if you are allergic to it or any other components of this medicine. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression, and severe liver disease. Hence, if you have any such conditions, inform your doctor. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause adverse effects. Metodox 50 mg Injection 1's is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.
Uses of Metodox 50 mg Injection 1's
Medicinal Benefits
Metodox 50 mg Injection 1's contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. Metodox 50 mg Injection 1's is also used in the treatment of acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumour, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma
Directions for Use
Side Effects of Metodox 50 mg Injection 1's
Drug Warnings
Metodox 50 mg Injection 1's should be avoided if you are allergic to it. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression and severe liver disease. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause serious adverse effects. Metodox 50 mg Injection 1's is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Do not stop receiving Metodox 50 mg Injection 1's without a doctor’s advice, as it can cause serious health conditions. Metodox 50 mg Injection 1's is known to cause secondary malignancies, tissue necrosis, cardiomyopathy and septic shock in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.
Drug-Drug Interactions
Drug-Food Interactions
Drug-Diseases Interactions
Drug-Drug Interactions Checker List
Habit Forming
Special Advise
According to postmarketing reports, juvenile children receiving doxorubicin hydrochloride are at risk of developing late cardiovascular dysfunction. Risk factors include early age during treatment (particularly five years), large cumulative dosages, and receipt of multimodal modality therapy. All pediatric patients who have received doxorubicin hydrochloride should undergo long-term cardiovascular monitoring.
Diet & Lifestyle Advise